Cara Therapeutics IncNASDAQ:CARANASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.2961
- TODAY'S CHANGE (%)-0.0126 (-4.0816%)
- Bid / Lots0.2920/ 175
- Ask / Lots0.3050/ 82
- Open / Previous Close0.2994 / 0.3087
- Day Range
- 52 Week Range
- Volume735,438
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CARA |
|---|---|---|
| 09:32 ET | 3128 | 0.2994 |
| 09:36 ET | 7000 | 0.3054 |
| 09:38 ET | 149 | 0.3053 |
| 09:43 ET | 1600 | 0.3053 |
| 09:45 ET | 285 | 0.3058 |
| 09:48 ET | 1600 | 0.3054 |
| 09:50 ET | 38052 | 0.31 |
| 09:54 ET | 6700 | 0.300931 |
| 09:57 ET | 200 | 0.3002 |
| 10:06 ET | 2042 | 0.2901 |
| 10:10 ET | 200 | 0.292 |
| 10:19 ET | 100 | 0.290201 |
| 10:24 ET | 1000 | 0.29985 |
| 10:28 ET | 100 | 0.292 |
| 10:33 ET | 1714 | 0.3049 |
| 10:39 ET | 100 | 0.3036 |
| 10:44 ET | 300 | 0.3036 |
| 10:46 ET | 200 | 0.3073 |
| 10:51 ET | 500 | 0.3073 |
| 10:57 ET | 617 | 0.291 |
| 11:04 ET | 500 | 0.3046 |
| 11:08 ET | 144 | 0.304 |
| 11:11 ET | 232 | 0.2974 |
| 11:15 ET | 293 | 0.2903 |
| 11:20 ET | 100 | 0.292 |
| 11:26 ET | 23000 | 0.2902 |
| 11:27 ET | 235 | 0.2938 |
| 11:29 ET | 170 | 0.3019 |
| 11:36 ET | 200 | 0.2935 |
| 11:47 ET | 100 | 0.2902 |
| 11:49 ET | 100 | 0.292 |
| 11:51 ET | 325 | 0.29585 |
| 11:58 ET | 100 | 0.296 |
| 12:07 ET | 2359 | 0.2962 |
| 12:12 ET | 400 | 0.3019 |
| 12:14 ET | 200 | 0.2962 |
| 12:43 ET | 500 | 0.2995 |
| 01:01 ET | 100 | 0.2948 |
| 01:03 ET | 1211 | 0.29475 |
| 01:17 ET | 100 | 0.2957 |
| 01:30 ET | 1200 | 0.295 |
| 01:39 ET | 100 | 0.2958 |
| 01:44 ET | 100 | 0.2958 |
| 02:02 ET | 100 | 0.2958 |
| 02:08 ET | 100 | 0.2958 |
| 02:09 ET | 150 | 0.2958 |
| 02:11 ET | 2485 | 0.29425 |
| 02:13 ET | 3300 | 0.2922 |
| 02:29 ET | 100 | 0.2995 |
| 02:31 ET | 200 | 0.2958 |
| 02:40 ET | 200 | 0.2995 |
| 02:44 ET | 138 | 0.2996 |
| 02:45 ET | 100 | 0.2959 |
| 02:49 ET | 167 | 0.2996 |
| 02:51 ET | 250 | 0.2922 |
| 02:54 ET | 167 | 0.2984 |
| 02:56 ET | 253 | 0.2959 |
| 02:58 ET | 167 | 0.2986 |
| 03:02 ET | 500 | 0.2995 |
| 03:07 ET | 585 | 0.292846 |
| 03:09 ET | 6932 | 0.2948 |
| 03:12 ET | 855 | 0.2966 |
| 03:16 ET | 100 | 0.2973 |
| 03:23 ET | 100 | 0.2973 |
| 03:27 ET | 100 | 0.2996 |
| 03:34 ET | 200 | 0.2996 |
| 03:41 ET | 100 | 0.2995 |
| 03:45 ET | 200 | 0.2973 |
| 03:48 ET | 1000 | 0.2986 |
| 03:50 ET | 4447 | 0.298 |
| 03:52 ET | 52949 | 0.3083 |
| 03:54 ET | 16493 | 0.3103 |
| 03:56 ET | 9796 | 0.2966 |
| 03:57 ET | 500 | 0.3103 |
| 03:59 ET | 271030 | 0.2961 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cara Therapeutics Inc | 16.9M | -0.1x | --- |
Turnstone Biologics Corp | 15.6M | -0.2x | --- |
SQZ Biotechnologies Co | 1.2M | 0.0x | --- |
Viaderma Inc | 7.2M | 0.0x | --- |
ImmuCell Corp | 28.4M | -6.9x | --- |
Eiger BioPharmaceuticals Inc | 12.6M | -0.2x | --- |
Company Information
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.
Contact Information
- Headquarters
- 400 Atlantic Street, Suite 500STAMFORD, CT, United States 06901
- Phone
- 203-406-3700
- Fax
- 203-567-1510
Executives
- Independent Chairman of the Board
- Martin Vogelbaum
- President, Chief Executive Officer, Director
- Christopher Posner
- Chief Financial Officer
- Ryan Maynard
- Chief Compliance Officer, General Counsel, Secretary
- Scott Terrillion
- Director
- Helen Boudreau
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $16.9M |
|---|---|
Revenue (TTM) | $11.0M |
Shares Outstanding | 54.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.70 |
EPS | $-2.04 |
Book Value | $1.05 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | 1.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,000.06% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
